A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002269
- Lead Sponsor
- HEM Research
- Brief Summary
To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Miami Veterans Administration Med Ctr
🇺🇸Miami, Florida, United States
Oregon Health Sciences Univ
🇺🇸Portland, Oregon, United States
MCP Hahnemann Univ Hosp
🇺🇸Philadelphia, Pennsylvania, United States
Dr Patricia Salvato
🇺🇸Houston, Texas, United States
Nelson Tebedo Community Clinic
🇺🇸Dallas, Texas, United States